| Literature DB >> 35329941 |
Laura Rojas-Bartolomé1, Óscar Ayo-Martín1, Jorge García-García1, Francisco Hernández-Fernández1, Elena Palazón-García1, Tomás Segura1,2.
Abstract
We aimed to evaluate the diagnostic value of orbital ultrasound in the etiologic diagnosis of central retinal artery occlusion (CRAO). For this purpose, patients with CRAO evaluated at our center between 2011 and 2021 were reviewed. Demographic variables, vascular risk factors and ultrasound findings were collected. An orbital duplex was performed in all cases and complemented with other diagnostic explorations. We attended 36 cases of CRAO. In all patients, orbital ultrasound confirmed the diagnosis of CRAO: in 75% emboli material (spot sign) was observed in CRA and in 25% flow alteration in CRA without visible embolus. The positive spot sign (PSS) group differed from patients with negative spot sign (NSS) in terms of etiology: 8 PSS cases (29.6%) had a major cardioembolic cause, 4 (14.8%) a large vessel atheromatous disease, 15 (55.6%) an undetermined cause. Some 21 (77.8%) PSS patients had some minor cardioembolic cause, mainly calcifications of the left valves. In the NSS group, 2 (22%) were diagnosed with giant cell arteritis (GCA). In CRAO, the ultrasound spot sign could be a guide for the detection of embolic sources. Its absence makes it necessary to consider more strongly the possibility of arteritis. Furthermore, our findings suggest a key role of calcium embolism in PSS patients.Entities:
Keywords: arterial occlusive diseases; central retinal artery occlusion; embolism; orbital ultrasound; retinal spot sign
Year: 2022 PMID: 35329941 PMCID: PMC8952198 DOI: 10.3390/jcm11061615
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1The absence of color and pulsed Doppler signal in the peripapillary portion of the CRA (diagnosis of CRAO). 3–9 MHz linear probe (Esaote MyLab70 and My Lab9, Esaote, Milan).
Figure 2Hyperechoic material in the retrobulbar circulation of the optic nerve (spot sign). Note the abscense of color code flow signal in the peripapillar segment of the CRA. 3–9 MHz linear probe (Esaote MyLab70 and My Lab9, Esaote, Milan).
Demographic characteristics and vascular risk factors.
| All Patients | PSS | NSS | |||
|---|---|---|---|---|---|
| Sample size, no. (%) | 36 | 27 (75) | 9 (25) | ||
| Women, no (%) | 14 (38.9) | 10 (37) | 4 (44.4) | 0.9 | |
| Age (mean ± SD) | 72.44 ± 12.01 | 72.07 ± 11.84 | 73.56 ± 13.2 | 0.75 | |
| Arterial hypertension, no. (%) | 29 (80.6) | 23 (85.2) | 6 (66.7) | 0.22 | |
| Hyperlipidaemia, no. (%) | 20 (55.6) | 16 (59.3) | 4 (44.4) | 0.44 | |
| Diabetes mellitus, no. (%) | 8 (22.2) | 7 (25.9) | 1 (11.1) | 0.35 | |
| Smoking, no. (%) | Smoker | 3 (8.3) | 2 (7.4) | 1 (11.1) | 0.68 |
| Ex-smoker | 10 (27.8) | 8 (29.6) | 2 (22.2) | ||
| Ischemic heart disease, no. (%) | 7 (19.4) | 6 (22.2) | 1 (11.1) | 0.46 | |
| Atheromatous artery disease, no. (%) | 4 (11.1) | 4 (14.8) | 0 | 0.27 | |
| Atrial fibrillation, no. (%) | 9 (25) | 8 (29.6) | 1 (11.1) | 0.26 | |
| Heart valve prosthesis, no. (%) | 3 (8.3) | 2(7.4) | 1 (11.1) | 0.72 | |
Complementary tests.
| Test | All Patients | PSS | NSS | |
|---|---|---|---|---|
| Cervical carotid ultrasound, no. (%) | 35 (97.2) | 26 (96.3) | 9 (100) | 0.56 |
| Orbital ultrasound, no. (%) | 36 (100) | 27 (100) | 9 (100) | - |
| Intracranial duplex, no. (%) | 30 (83.3) | 21 (77.7) | 9 (100) | 0.07 |
| Temporal and occipital artery duplex, no (%) | 14 (39) | 12 (44.4) | 2 (22.2) | 0.23 |
| Angio-CT of the circle of Willis, no. (%) | 7 (19.4) | 4 (14.8) | 3 (33.3) | 0.16 |
| Right-to-left cardiac shunt, no. (%) | 2 (6) | 2 (7.4) | 0 | 0.4 |
| Echocardiography, no. (%) | 29 (81) | 24 (88.9) | 5 (55.6) | 0.03 |
| EKG monitoring, no. (%) | 20 (55.6) | 17 (63) | 3 (33.3) | 0.12 |
| Admitted to the stroke unit, no. (%) | 16 (44.4) | 13 (48.1) | 3 (33.3) | 0.43 |
| Ambulatory Holter monitoring, no. (%) | 4 (11.1) | 4 (14.8) | 0 | 0.16 |
CRAO etiology by TOAST classification.
| TOAST Etiology | PSS | NSS | Total | |
|---|---|---|---|---|
| Undetermined, no. (%) | 15 (55.6) | 2 (22.2) | 17 (47.2) | 0.083 |
| Cardioembolic, no. (%) | 8 (29.6) | 1 (11.1) | 9 (25) | 0.267 |
| Atrial fibrillation | 7 | 1 ‡ | 8 (22.2) | |
| Mechanical heart valve prosthesis | 1 † | 0 | 1 † (2.7) | |
| Marantic endocarditis | 1 | 0 | 1 (2.7) | |
| Atheromatous large-vessel disease, no. (%) | 4 (14.8) | 4 (44.4) | 8 (22.2) | 0.22 |
| Ipsilateral ICA stenosis occlusion | 0 | 3 | 3 (8.3) | |
| Ipsilateral significant ICA stenosis (≥50%) cervical or supraclinoid | 4 | 1 | 5 (13.8) | |
| GCA, no. (%) | 0 | 2 (22.2) | 2 (5.6) | 0.012 |
† Case with heart valve prosthesis and atrial fibrillation. ‡ Ipsilateral ICA stenosis occlusion due to cardiac embolism. Giant cell arteritis (GCA); internal carotid artery (ICA).
Minor cardioembolic sources.
| Minor Cardioembolic Sources | PSS | NSS | Total | |
|---|---|---|---|---|
| Biologic heart valve prosthesis | 1 (3.7%) | 1 (11.1%) | 2 (5.6%) | 0.4 |
| Left heart valves calcifications | 19 (70.4%) | 1 (11.1%) † | 20 (55.6%) | 0.002 |
| Right-to-left cardiac shunt | 1 (3.7%) | 0 | 1 (2.8%) | 0.55 |
| All minor cardioembolic sources | 21 (77.8%) | 1 (11.1%) † | 22 (61.1%) | 0 |
† Case of the NSS group with heart valve prosthesis and left valvular calcifications (atheromatous etiology). Positive spot sign group (PSS); Negative spot sign group (NSS).